Skip to main content
. 2023 Nov 23;29(3):200–212. doi: 10.1093/oncolo/oyad306

Table 4.

Selected studies evaluating the role of MRD to determine treatment.

Study Patient population Timing of MRD assessment Technique
PERSEUS (NCT03710603) TE-NDMM 1-2 years into MT NGS
DRAMATIC (NCT04071457) TE-NDMM 2 years post MT NGS
MASTER (NCT03224507) TE-NDMM Post induction, ASCT, and consolidation NGS
EMN 20 (NCT04096066) TIE-NDMM 1-2 years of MT NGS

Abbreviations: TE-NDMM, transplant eligible newly diagnosed multiple myeloma; TIE-NDMM, transplant ineligible newly diagnosed multiple myeloma; MT, maintenance treatment; ASCT, autologous stem cell transplant; NGS, next generation sequencing; MRD, minimal residual disease.